BTIG Downgrades Taysha Gene Therapies to Neutral
BTIG analyst Yun Zhong downgrades Taysha Gene Therapies (NASDAQ:TSHA) from Buy to Neutral.
US Stocks Turn Higher After Fed Raises Key Overnight Interest Rate; Nasdaq Up 1.5%
U.S. stocks turned higher toward the end of trading, following the release of interest rate decision.
The Dow traded up 0.05% to 34,104.56 while the NASDAQ rose 1.58% to 11,767.44. The S&P 500 also fell, dropping, 0.83% to 4,110.42.
Dow Dips 300 Points; Snap Shares Plunge
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 300 points on Wednesday.
The Dow traded down 0.91% to 33,774.70 while the NASDAQ fell 0.33% to 11,546.13. The S&P 500 also fell, dropping, 0.41% to 4,059.70.
Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $13
Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $17 to $13.
Truist Securities Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $4
Truist Securities analyst Joon Lee maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $15 to $4.
JMP Securities Maintains Market Outperform on Taysha Gene Therapies, Lowers Price Target to $4
JMP Securities analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and lowers the price target from $6 to $4.